Status:
COMPLETED
Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive
Lead Sponsor:
Bayer
Conditions:
Contraception
Eligibility:
FEMALE
18-50 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to confirm the safety of SH T00658ID with regard to plasma lipids, hemostatic variables, and carbohydrate metabolism. In addition, the pharmacokinetic parameter following ...
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Healthy female volunteers between 18 and 50 years requiring contraception
Exclusion
- Pregnancy or lactation
- Any conditions that might interfere with the outcome as well as all contraindications for OC use
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00185224
Start Date
March 1 2005
End Date
March 1 2006
Last Update
July 15 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayer Schering Pharma AG - Clin. Pharm. Berlin
Berlin, State of Berlin, Germany, 13342